AutoAsmaAlert: Technological tool to prevent Salbutamol Overuse in a Colombian Healthcare Provider "Letter to the Editor"

Miguel Angel Arroyo Alzate (Medical Affairs Department, AstraZeneca-Andean Cluster)
Christian Adrián López-Castillo (Medical Affairs Department, AstraZeneca-Andean Cluster)
Laura Bernal-Villada (Medical Affairs Department, AstraZeneca-Andean Cluster)
Walberto Buelvas (MediSinu IPS. Colombia)
Karen de Oro (MediSinu IPS. Colombia)
Juan Camilo Rivera (Triario SAS. Colombia)
Santiago Pinilla (IT Department, AstraZeneca-Andean Cluster)
Paula Garcia (IT Department, AstraZeneca-Andean Cluster)
Paola Rivero (IT Department, AstraZeneca-Andean Cluster)
Maribeb Almanza (Market Access Department, AstraZeneca-Andean Cluster)
Leonor Gonzalez (Market Access Department, AstraZeneca-Andean Cluster)

Health and Technology Journal (HTECHJ)
Vol. 2 No. 3 (2024): June 2024

The use of Salbutamol for the treatment of asthma has been a part of regular therapy as a short-acting β2-agonist since the 1960s. In the GINA 2024 guidelines, it is indicated that the use of salbutamol in monotherapy has been associated with increased mortality and poor asthma control. Therefore, the development of alternatives that allow rapid identification of its overuse is of great interest for the management of the disease. In order to achieve this objective, it was proposed to develop the technological tool, Auto Asthma Alerts “AAA”, with the aim to identifying in the clinical history and in real time the overuse of SABA (more than 3 inhalers per year) and thus alert physicians. The platform was successfully trialled on a pilot scale in a healthcare institution in Montería, Colombia, MediSinu IPS.